Allergan Q3 2009 Earnings Call Transcript

Oct. 29, 2009 8:30 PM ETAllergan plc (AGN)
SA Transcripts profile picture
SA Transcripts

Allergan, Inc. (NYSE:AGN) Q3 2009 Earnings Call October 29, 2009 11:00 AM ET


Jim Hindman - Investor Relations

David E.I. Pyott - Chairman and Chief Executive Officer

Jeffrey L. Edwards - Executive Vice President, Finance and Business Development and Chief Financial Officer

Scott M. Whitcup, M.D. - Executive Vice President, Research and Development

Joann Bradley - Investor Relations


Frank Pinkerton - SunTrust Robinson Humphrey

Marc Goodman - UBS Securities LLC

Annabel Samimy - Thomas Weisel Partners LLC

David Buck - Buckingham Research Group

Gregg Gilbert - BAS-ML

John Boris - Citigroup

Peter J. Bye - Jefferies and Company

Aaron Ronny Gal - Bernstein Research

Larry Biegelsen - Wells Fargo Securities LLC


Hello and welcome to the Allergan Third Quarter 2009 Earnings Call. Following today's presentation, there will be a formal question-and-answer session. (Operator Instructions). Until then, all lines will remain on listen-only mode. As a request of the company, today's conference is being recorded. If anyone has any objections, you may disconnect at this time.

I would like to introduce today's conference host, Mr. Jim Hindman, Senior Vice President, Treasury Risk and Investor Relation. Sir, you may begin.

Jim Hindman

Thank you, Jerry. Good morning.

With me for today's conference call is David Pyott, Chairman of the Board and Chief Executive Officer, Jeff Edwards, Executive Vice President, Finance and Business Development, Chief Financial Officer, Dr. Scott Whitcup, Executive Vice President, Research and Development, Chief Scientific Officer, and Jim Barlow, Senior Vice President and Corporate Controller.

Before we move ahead, I would like to remind you that certain statements that we will make in this presentation are forward-looking statements. These forward-looking statements reflect Allergan's judgment and analysis only as of today, and actual results may differ materially from current expectations based on a number of factors affecting Allergan's businesses.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.